|
|
|
|
|
 |
| Welcome
to Oncology Europe
28.08.2008 |
 |
This
website has been created to help inform and support physicians treating cancer
patients. It includes publications, conference reports, new data and concise
information
in the field of oncology.
|
|
What's new on Oncology Europe
|
|
|
|
Nov 14-15, 2008
ESH - EHA Tutorial on Haematological Malignancies
Dublin, Ireland
|
|
Read more... |
|
|
Topic
review EGFR
EGFR in cancer
Detailed Topic review on
EGFR in nine articles |
|
Read more... |
|
|
Site
of the
European Organisation
for Research and Treatment of Cancer
|
|
Read more...
|
|
  | Admission of Cetuximab In First-Line As Well
29.08.2008
New analyses of the CRYSTAL- and OPUS data presented at this year’s ASCO meeting confirm in the first-line setting and in large patient collectives, that the effectivity of Cetuximab (Erbitux®) is considerably increased in advanced colorectal carcinoma if the KRAS oncogene in the tumor tissue is not yet mutated. For the first time, the KRAS mutation status has been deemed a predictive biomarker in large Phase-III studies – a progress that may be soon reflected in a change of admissions: the EMEA’s Committee for Human Medicinal Products (CHMP) has assessed the extension of admission for Cetuximab on May 30 positively also in the first-line treatment of patients with mCRC with wild type KRAS.
Read more...
 |
| Update on Gastrointestinal Tumors
28.08.2008
According to current study data presented at this year`s ASCO meeting in Chicago, the therapy of gastrointestinal tumors is on the move. For the first time, therapeutic success in terms of healing has been verified in a retrospective study in patients with colorectal carcinoma and liver metastases.
Read more...
|
| Diagnostics in early NSCLC: PET superior
27.08.2008
This 3rd part of the ASCO-highlights article reviews the latest findings in the field of imaging in early NSCLC and antiangiogenesis in breast cancer. Part 1 of this article discusses the therapy of anaplastic gliomas, and part 2 focuses on mTOR inhibition in mantle cell lymphoma.
Read more...
|
| Mantle cell lymphoma: mTOR inhibition prolonges PFS
26.08.2008
More highlights from the world’s largest oncological meeting: According to an international phase III study, the mTOR inhibitor temsirolimus significantly prolonges PFS of pretreated patients with mantle cell lymphoma. Experts are now calling for an investigation into the efficacy of this drug in earlier stages of the disease. Part 1 of this article discusses the therapy of anaplastic gliomas, part 3 reviews the latest findings in imaging of early NSCLC and antiangiogenesis in breast cancer.
Read more...
|
| Anaplastic gliomas: sequence of therapeutic modalities irrelevant
25.08.2008
The world’s largest oncology congress took place for the second consecutive time in Chicago. With more than 30.000 participants and at times more than 20 parallel meetings it is only possible to take advantage of a tiny part of the program on offer.
These 3 articles form a report on the ASCO highlights – on the premises that only very few of the many highlights to chose from made it into this final subjective selection. Part 2 focuses on mTOR inhibition in mantle cell lymphoma, part 3 reviews the latest findings in imaging of early NSCLC and antiangiogenesis in breast cancer.
Read more...
|
| Notedly improved survival chances for young patients
22.08.2008
The ABCSG-12 study presented at this year’s ASCO created an international furore with its surprising result that adjuvant administration of zoledronate can significantly reduce the recidivation risk in hormone-receptor positive breast cancer in stage I or II. Jatros Haematology & Oncology interviewed the president of the Austrian Breast & Colorectal Cancer Study Group, Prof. Michael Gnant, University Clinic for Surgery, Medical University of Vienna, on the topic of the promising bisphosphonate.
Read more...
|
|
Next >
Service-Center: Power Point Presentations >
onco-europe-portal: New Stuff >
Oncological-Societies Europe >
All articles > 
Archive > |
|
|
|
|
|
|
|